Clinical Trial Update: A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This document describes a Phase 1/2 clinical trial evaluating the combination of gilteritinib and momelotinib in relapsed or refractory FLT3-mutated acute myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gilteritinib (gilteritinib)
• Momelotinib (momelotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloid Leukemia | Phase 1, Phase 2 | Status: RECRUITING